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Abstract
Background: The adverse health effects of early life exposure to tobacco smoking have been widely reported. In
spite of this, the underlying molecular mechanisms of in utero and postnatal exposure to tobacco smoke are only
partially understood. Here, we aimed to identify multi-layer molecular signatures associated with exposure to
tobacco smoke in these two exposure windows.
Methods: We investigated the associations of maternal smoking during pregnancy and childhood secondhand
smoke (SHS) exposure with molecular features measured in 1203 European children (mean age 8.1 years) from the
Human Early Life Exposome (HELIX) project. Molecular features, covering 4 layers, included blood DNA methylation
and gene and miRNA transcription, plasma proteins, and sera and urinary metabolites.
Results: Maternal smoking during pregnancy was associated with DNA methylation changes at 18 loci in child
blood. DNA methylation at 5 of these loci was related to expression of the nearby genes. However, the expression
of these genes themselves was only weakly associated with maternal smoking. Conversely, childhood SHS was not
associated with blood DNA methylation or transcription patterns, but with reduced levels of several serum
metabolites and with increased plasma PAI1 (plasminogen activator inhibitor-1), a protein that inhibits fibrinolysis.
Some of the in utero and childhood smoking-related molecular marks showed dose-response trends, with stronger
effects with higher dose or longer duration of the exposure.
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Conclusion: In this first study covering multi-layer molecular features, pregnancy and childhood exposure to
tobacco smoke were associated with distinct molecular phenotypes in children. The persistent and dose-dependent
changes in the methylome make CpGs good candidates to develop biomarkers of past exposure. Moreover,
compared to methylation, the weak association of maternal smoking in pregnancy with gene expression suggests
different reversal rates and a methylation-based memory to past exposures. Finally, certain metabolites and protein
markers evidenced potential early biological effects of postnatal SHS, such as fibrinolysis.
Keywords: Tobacco smoking, Secondhand smoke, Children, Pregnancy, Omics, Molecular phenotypes, DNA
methylation, Transcription, miRNA, Metabolomics
Background
The in utero period and the first years of human life are
crucial for the development and maturation of organs
[1]. Insults during these periods may result in later ad-
verse health consequences, which might persist during
the whole lifespan. This is known as the Developmental
Origins of Health and Disease (DOHaD) concept [2].
Maternal smoking during pregnancy represents one of
the most important avoidable risk factors, and its short-
and long-term adverse effects on offspring, including
prematurity, lower birth weight, increased risk of asthma
and obesity, and impaired neurodevelopment, have been
widely reported [3, 4]. In 15 European countries, the
prevalence of maternal smoking at any time during preg-
nancy ranged between 4.2 and 18.9% in 2011–2012 [5].
Secondhand smoke (SHS) is one of the main contribu-
tors to the indoor air pollution, with 40% of children ex-
posed worldwide in 2004 [6]. In Europe between 1999
and 2008, among never-smoking adolescents, around
50%, 70%, and 45% were exposed to SHS inside home,
outside home, and both, respectively [7]. SHS has been
related to increased risk of asthma, lower respiratory in-
fections, and sudden infant death syndrome [4, 6].
The molecular alterations resulting from tobacco smoke
exposure are only partially understood. Their study can facili-
tate the development of biomarkers of exposure that surpass
the limitations of existing ones, such as questionnaires and
urinary cotinine, which only informs about recent exposure
[8, 9]. For instance, the first epigenetic biomarker of maternal
smoking allowed the discrimination between exposed and
unexposed children with an accuracy > 90% [10]. They may
also provide knowledge on the molecular mechanisms that
could mediate the effects of tobacco smoking on health. For
instance, it has been described that epigenetic deregulation
of JNK2 gene by maternal smoking during pregnancy is asso-
ciated with impaired lung function in early childhood [11].
Also, methylation levels of maternal smoking-related CpGs
in adolescents/adults have been causally linked through
Mendelian randomization to inflammatory bowel disease
and schizophrenia [12]. Moreover, molecular responses
might be more sensitive and earlier markers of a biological
effect than clinical outcomes.
In this line, several studies have shown that maternal
smoking in pregnancy is associated with altered patterns
of DNA methylation at birth, in placenta [13] and in
cord blood [11, 14–16]. Interestingly, some of the mater-
nal smoking-related blood loci show persistent dysregu-
lation until childhood [15, 16], adolescence [16, 17], or
even adulthood [18]. However, not much is known
about the transcriptional consequences of these persist-
ent DNA methylation changes [15]. Furthermore, while
the alterations at multiple molecular layers, from epigen-
etics to metabolomics, have been investigated in relation
to current smoking in adults [19–22], there is lack of in-
formation about the multi-layer molecular changes asso-
ciated with in utero exposure or with the exposure to
SHS in children. Regarding adult SHS exposure, only
DNA methylation candidate studies are available [23].
Here, we aimed to identify multi-layer molecular sig-
natures associated with exposure to tobacco smoke in
two early life susceptibility windows, in utero due to ma-
ternal smoking and in childhood through exposure to
SHS. For this, we used molecular data from 1203 chil-
dren of the Human Early Life Exposome (HELIX) study,
including child blood DNA methylation and transcrip-
tion, plasma proteins, and sera and urinary metabolites.
Methods
Study population
The Human Early Life Exposome (HELIX) study is a
collaborative project across 6 established and ongoing
longitudinal population-based birth cohort studies in
Europe [24]: the Born in Bradford (BiB) study in the UK
[25]; the Étude des DÉterminants prÉ et postnatals du
dÉveloppement et de la santÉ de l’Enfant (EDEN) study
in France [26]; the INfancia y Medio Ambiente (INMA)
cohort in Spain [27]; the Kaunas cohort (KANC) in
Lithuania [28]; the Norwegian Mother, Father and Child
Cohort Study (MoBa) [29]; and the RHEA Mother Child
Cohort study in Crete, Greece [30]. Around age 8 years,
the HELIX follow-up visit of the offspring took place
using harmonized questionnaires and sampling protocols
(n = 1301). HELIX children with complete data on pre-
natal and postnatal variables of exposure to tobacco
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smoking and with data on at least one omics platform
were selected for the present study (n = 1203). Years of
enrollment, years of HELIX visit, and years of smoking
prohibition in each cohort are shown in Additional file 1:
Table S1.
Biological samples
At the HELIX follow-up visit, child peripheral blood was
collected and processed into a variety of sample matri-
ces: buffy coat, serum, plasma, and whole blood. Median
fasting time was 3.5 h (SD = 1.1 h). Two spot urine sam-
ples (one before bedtime and one first morning void)
were collected at the participants’ home and transported
at 4 °C to the cohort center, where they were combined
at equal volumes to create a daily urine pool. In the
HELIX follow-up, the daily urine pool was available for
92.90% of the children, while the first morning and bed-
time urines were available for 3.14% and 3.96% of the
children, respectively. All sample types were stored at −
80 °C until processed.
Exposure to tobacco smoking
Definitions of exposure to tobacco smoking in pregnancy
Maternal smoking habits during pregnancy were ob-
tained from existing data collected in each cohort using
non-harmonized questionnaires administered to the
mothers in at least the first and third trimester of preg-
nancy. Two variables for active maternal smoking during
pregnancy were generated: (i) any maternal smoking
during pregnancy if the mother had smoked at any time
during pregnancy (“yes/no”), and (ii) sustained maternal
smoking, if the mother had smoked, at least, in the 1st
and in the 3rd trimester (“yes/no”). The mean number
of cigarettes smoked per day during pregnancy was esti-
mated averaging the mean number of cigarettes per day
in the first and third trimesters.
Maternal exposure to SHS in pregnancy (mother-SHS:
“yes/no”) was assessed through questionnaire and was
slightly different between cohorts: (i) exposure at home,
work, or leisure places (INMA); (ii) exposure at home or
work (MoBa, RHEA, BiB); (iii) exposure without specify-
ing location (EDEN); and (iv) partner smoking (KANC).
We combined all previous definitions to create a vari-
able that captured both dose and duration of exposure
to smoking during pregnancy with the following categor-
ies: “unexposed,” “SHS,” “non-sustained smoker,” “sus-
tained smoker at low dose (≤ 9 cigarettes per day),” and
“sustained smoker at high dose (> 9 cigarettes per day).”
Definitions of childhood exposure to secondhand smoke
Childhood exposure to secondhand smoke (SHS) was
assessed through a harmonized questionnaire adminis-
tered to the parents as part of the HELIX project. The
questionnaire included questions about (i) smoking at
home by the mother, mother’s partner, or other people,
and (ii) attendance to indoor places where people smoke.
From this information, we created a variable of SHS with
four levels: “unexposed,” “exposed to SHS only outside
home,” “exposed to SHS only inside home,” and “ex-
posed to SHS inside and outside home.” This variable
was reclassified in larger groups to assess global expos-
ure to SHS (global-SHS: “yes/no”; home-SHS: “yes/no”).
Urinary cotinine levels were measured in the children
using the Immulite2000 Nicotine Metabolite (Cotinine)
600 Test on an Immulite 2000 XPi from Siemens
Healthineers at Fürst Medisinsk Laboratorium in
Norway for which the LOD was 3.03 μg/L. Due to low
concentrations in children, a categorical variable was
created (cotinine: “detected/undetected”).
Correlation between exposure variables
The correlation among the proportion of exposed chil-
dren using different smoking definitions and different
windows of exposure was calculated using the tetracho-
ric correlation test, with the psych R package [31]. The
tetrachoric correlation estimates what the correlation
would be if measured on a continuous scale.
Molecular phenotypes
Detailed information on molecular characterization of
the 4 molecular layers (6 omics datasets) can be found
in Additional file 2: Additional Methods [32–49].
Blood DNA methylation
Briefly, methylation was measured in DNA extracted from
buffy coat (EDTA tube) using the Infinium HumanMethy-
lation450 beadchip (Illumina, USA) at the Spanish National
Genotyping Center (CeGen, Spain). Samples were random-
ized and balanced by sex and cohort within each batch.
Samples with low call rate (< 98%) were excluded. Also,
probes with low call rate (< 95%) [32], probes in sexual
chromosomes, cross-hybridizing probes, and probes con-
taining single nucleotide polymorphisms (SNPs) were fil-
tered out [34]. Methylation levels were normalized using
the functional normalization method with prior back-
ground correction with Noob [33], and slide batch effect
was controlled with the ComBat method [36]. Beta values,
going from 0 (un-methylated) to 1 (fully methylated), were
used in the analyses. CpGs were annotated with the Illumi-
naHumanMethylation450kanno.ilmn12.hg19 R package
[35]. Blood methylation quantitative trait loci (mQTL) were
retrieved from mQTLdb (http://www.mqtldb.org/) (data-
base: MatrixEQTL; timepoint: childhood; distance: 1Mb).
Blood gene expression
RNA was extracted from whole blood collected in Tem-
pus tubes. Gene expression was assessed using the Gen-
eChip® Human Transcriptome Array 2.0 (HTA 2.0)
Vives-Usano et al. BMC Medicine          (2020) 18:243 Page 3 of 19
(Affymetrix, USA) at the University of Santiago de Com-
postela (USC, Spain). Samples were randomized and bal-
anced by sex and cohort within each batch. Data was
normalized at the gene level with the GCCN (SST-
RMA) algorithm, and batch effects and blood cell type
composition were controlled with two surrogate variable
analysis (SVA) methods, isva [38] and SmartSVA [39],
during the differential expression analyses. Gene expres-
sion values were log2 transformed, and annotation of
transcript clusters (TCs) to genes was done with the
Affymetrix Expression Console software using the HTA-
2_0 Transcript Cluster Annotations Release na36 (hg19).
Blood miRNA expression
miRNA expression was quantified using the SurePrint
Human miRNA Microarray rel.21 (Agilent Technologies,
USA) [42], at the Genomics Core Facility at the Centre
for Genomic Regulation (CRG, Spain). Samples were
randomized and balanced by sex and cohort within each
batch. miRNA expression levels were normalized with
the least variant set (LVS) method [43] with background
correction with the Normexp method [44]. Normalized
miRNA levels were log2 transformed and annotated
using a combination of information from Agilent anno-
tation (“Annotation_7056”) and miRbase v21 (GRCh38
and mapped back to hg19) released in January 2017.
Additional control of batch effect and blood cell com-
position during the differential expression analyses was
done with the SVA standard method [45].
Plasma proteins
Plasma protein levels were assessed using the antibody-
based multiplexed platform from Luminex at the Proteo-
mics Unit (Centre for Genomic Regulation (CRG)/Uni-
versity Pompeu Fabra (UPF), Spain), using 3 commercial
kits (Thermo Fisher Scientific, USA): Cytokines 30-plex
(catalog number (CN): LHC6003M), Apoliprotein 5-plex
(CN: LHP0001M), and Adipokine 15-plex (CN:
LHC0017M) (Additional file 1: Table S2). All samples
were randomized and blocked by cohort. Raw intensities
were converted to nanograms per milliliter (5-plex kit)
and to picograms per milliliter (15- and 30-plex kits)
using 8-point calibration curves added in each plate.
Only 36 proteins out of 43 with > 30% of measurements
in the linear range of quantification were kept for the
analysis. Protein levels were log2 transformed, and plate
batch effect was corrected. Values below the lower limit
of quantification (LOQ1) and above the upper limit of
quantification (LOQ2) were imputed using the truncdist
R package [46].
Serum metabolites
Serum metabolites were quantified using the targeted
metabolomics Absolute-IDQTM p180 Kit (Biocrates Life
Sciences AG, USA). Serum metabolic profiles were ac-
quired following the manufacturer’s protocol using LC-
MS/MS on a Sciex QTrap 6500 equipped with an Agi-
lent 1100 series HPLC (Agilent Technologies, USA), at
Imperial College London (ICL, UK); a full description of
the HELIX metabolomics methods and data can be
found elsewhere [47]. Samples were fully randomized.
Metabolites were quantified (mM) following the manu-
facturer’s protocol (appendix), and then log2 trans-
formed. Metabolite exclusion was based on a metabolite
variable meeting two conditions: (1) CV of over 30% and
(2) over 30% of the data are below LOD. Eleven out of
the 188 serum metabolites detected were excluded as a
result, leaving 177 serum metabolites to be used for fur-
ther statistical analysis. The mean coefficient of variation
across the 177 LC-MS/MS detected serum metabolites
was 16%. Analytical performance was in line with expec-
tations from and inter-laboratory ring trial of this plat-
form [48].
Urinary metabolites
Urinary metabolic profiles were analyzed on a 14.1-T
(600 MHz 1H) NMR spectrometer (Bruker, USA) at Im-
perial College London (ICL, UK) [47]. Urine samples
were fully randomized. In addition, 60 identical study
quality control urine samples were included at regular
intervals during the runs. While data acquisitions were
untargeted, data processing workflow followed a targeted
strategy to identify and quantify the 44 most abundant
metabolites in urine [47, 49]. Sample concentration of a
given metabolite was estimated from the signal of the in-
ternal standard trimethylsilylpropanoic (TSP). Data was
normalized using median fold change normalization
method which takes into account the distribution of
relative levels from all 44 metabolites compared to the
reference sample in determining the most probable dilu-
tion factor. Twenty-six metabolites were absolutely
quantified, and 18 semi-quantified. Concentration levels
were expressed as log2, and before that, we used an off-
set of ½ the minimal value for each metabolite.
Statistical analyses
Analysis steps
The steps to analyze the HELIX data were as follows: (1)
We systematically analyzed the association between
period-specific exposure to tobacco smoke and child
molecular marks from the different omics layers. (2) For
statistically significant molecular marks, we tested the ef-
fect of dose and duration of the exposure. (3) For CpGs
only, we searched for cis expression quantitative trait
methylation (eQTM). (4) We contrasted our findings
with the previous literature, either through direct com-
parison or through enrichment analyses. (5) We con-
ducted sensitivity analyses to test the robustness of the
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findings to exposure definitions, period-specific effects,
and ancestry.
Association between exposure to smoking and molecular
phenotypes
To test the relationship between exposure to tobacco
smoke versus child molecular marks, we fitted linear re-
gressions between each tobacco smoking variable (pre-
dictor) and each molecular mark (outcome) adjusting
for covariates, using limma [44] within the implementa-
tion of omicRexposome R package [41]. Children unex-
posed to tobacco smoke, in each definition and period,
were considered the reference group. Since we wanted
to assess period-specific smoking effects, models were
mutually adjusted: any and sustained maternal smoking
in pregnancy were adjusted for childhood global-SHS,
while childhood global-SHS and urinary cotinine detec-
tion were adjusted for sustained maternal smoking in
pregnancy.
Other covariates were selected through directed acyc-
lic graphs (DAGs) with the DAGitty tool [50] (Add-
itional file 3: Fig. S1; and Additional file 3: Fig. S2). The
following variables were selected for both periods: (i) co-
hort, (ii) self-reported ancestry (European ancestry, Paki-
stani or Asian, and others), (iii) maternal age, and (iv)
self-reported maternal education (low (primary school),
medium (secondary school), and high (university degree
or higher)). In addition, pregnancy models were adjusted
for maternal obesity status, and childhood models for
child body mass index (zBMI). Maternal BMI was calcu-
lated from pre- or early-pregnancy weight and height
and divided in four categories derived from World
Health Organization (WHO) definitions. Child zBMI is a
sex and age z-score calculated according to WHO refer-
ence curves [51, 52]. Single imputation of missing data
for covariates was done using a chained equations
method [53] with the mice R package [54]. The propor-
tion of missing data in the selected covariates was min-
imal: 0.17% in maternal age, 0.75% in maternal BMI, and
2.16% in maternal education. Apart from covariates
resulting from DAG diagrams, models were also ad-
justed for sex and child age, as well as for specific covari-
ates in models of each of the omics. Methylation models
were adjusted for blood cell type composition (CD4+
and CD8+ T cells, natural killer cells (NK), monocytes,
granulocytes, and B cells), which was estimated from
raw methylation data [55, 56]. Models of plasma proteins
and serum metabolites were adjusted for time to last
meal and hour of blood collection, and models for urine
were adjusted for sample type (morning, night, or the
pool of both). Serum and urinary metabolites were add-
itionally corrected for technical batch. Technical batch
effects of the other omics datasets were eliminated
during the quality control process, as described in previ-
ous sections.
Multiple-testing correction was performed within each
molecular layer following different approaches. For
omics with more than 1000 features (methylation, gene
expression, and miRNAs), we used false discovery rate
(FDR)–Benjamini-Hochberg correction [57]. For the
remaining omics, we divided the nominal p value by the
effective number of tests [58] (proteins—18.4, p value =
2.72E−03; serum metabolites—60.3, p value = 8.29E−04;
urinary metabolites—33.3, p value = 1.50E−03).
The effect of smoking on DNA methylation is reported
as a difference in methylation levels between exposed
and unexposed children, while for the other omics, the
effect is reported as a log2 fold change (log2FC). To
examine whether different definitions of exposure (i.e., any
vs. sustained) or different adjustments yielded increased or
decreased magnitudes of association, we calculated the per-
cent change in the coefficients (β) between the two models
(i.e., sign(max(βSust.;βAny) × (βSust. − βAny)/|βAny| × 100)).
Dose and duration of the effect
To study the effect of dose and duration during preg-
nancy, we fitted linear regressions between the levels of
the molecular biomarker (outcome) and the exposure to
tobacco smoking (predictor) defined in the following
categories: “unexposed,” “SHS,” “non-sustained smoker,”
“sustained smoker at low dose (≤ 9 cigarettes per day),”
and “sustained smoker at high dose (> 9 cigarettes per
day),” where “unexposed” was the reference category.
Similarly, for the childhood exposure, we fitted linear re-
gressions between the levels of the molecular biomarker
(outcome) versus the exposure to tobacco smoking (pre-
dictor) defined in the following categories: “unexposed,”
“exposed to SHS only outside home,” “exposed to SHS
only inside home,” and “exposed to SHS inside and out-
side home,” where “unexposed” was considered the ref-
erence category.
Expression quantitative trait methylation
For CpGs significantly associated with exposure to to-
bacco smoke, we searched for cis eQTMs using methyla-
tion and gene expression data from 874 HELIX children.
Cis effects were defined in a window of 1Mb from the
transcription start site (TSS) of each TC (each gene).
The association between DNA methylation and gene ex-
pression levels was assessed via 1420 linear regressions.
Models were adjusted for cohort, child’s age, sex, zBMI,
ancestry, and blood cell type composition. To control
for gene expression batch effect, we estimated surrogate
variables (SVs) with the SVA R package [45], protecting
covariates (cohort, child’s age, sex, zBMI, ancestry, and
blood cell type composition), and the effect of these SVs
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was eliminated from the gene expression matrix by cal-
culating the residuals.
Direct comparison with the literature and enrichment
analyses
We compared findings in our study with previous litera-
ture on the molecular effects of exposure to tobacco
smoke in pregnancy (DNA methylation [15]) and of own
smoking in adults (DNA methylation [21], gene expres-
sion [20], miRNA expression [22], serum metabolites
[19]). When possible, we did a detailed comparison with
previous findings; for genome-wide omics without sig-
nificant marks in our study, we conducted enrichment
analyses. To explore enrichment of our results for mo-
lecular marks (CpGs/genes) identified previously for
current smoking in adults, we tested whether the distri-
bution of p values at these marks in our data deviates
from a null distribution using one-sided Kolmogorov-
Smirnov tests, and compared the direction of effect esti-
mate to what was reported previously.
Sensitivity analyses
On the molecular marks that survived multiple-testing
correction, we performed sensitivity analyses to test the
robustness of results under the following scenarios: (i)
for models of any and sustained maternal smoking in
pregnancy, we tested the effect of adjusting for home-
SHS, instead of global-SHS; (ii) we compared main
models, which are mutually adjusted for the two expos-
ure periods (i.e., maternal smoking in pregnancy ad-
justed for childhood SHS), versus unadjusted models
(i.e., maternal smoking in pregnancy without adjustment
for childhood SHS); and (iii) finally, we restricted the
analysis to children of European ancestry (N = 1083).
All the analyses were done in R environment. The R
packages MultiDataSet [59], rexposome, and omicRex-
posome [41] were used to manage and analyze the omics
and exposure data. ggplot2 [60], qqman [61], calibrate
[62], sjPlot [63], OmicCircos [64], and coMET [65] R
packages were used to visualize the results.
Results
Study population
The study included 1203 children, aged 6 to 11 years,
from the Human Early Life Exposome (HELIX) project
that had complete information on pregnancy and child-
hood exposure to tobacco smoking and data on at least
one omics platform [24]. These children were from lon-
gitudinal cohorts in 6 European countries, 90.1% were of
European ancestry, 54.5% were males, and 51.5% were
born from highly educated mothers (Table 1). Molecular
features measured at an average age of 8.1 years included
blood DNA methylation, blood gene and miRNA expres-
sion, plasma proteins, and sera and urinary metabolites
Table 1 Description of the HELIX study participants (n = 1203)
Variable n (%) or mean (SD)
Cohort
BiB (UK) 176 (14.6)
EDEN (France) 171 (14.2)
INMA (Spain) 215 (17.9)
KANC (Lithuania) 189 (15.7)
MoBa (Norway) 255 (21.2)




Child age (years) 8.1 (1.6)
Child zBMI* 0.4 (1.2)
Child ancestry
European 1083 (90.1)
Pakistani or Asian 93 (7.7)
Others 27 (2.2)
Maternal age (years) 30.8 (4.8)
Maternal BMI categories
< 18.5 46 (3.8)
18.5–24.9 691 (57.4)
25–29.9 295 (24.5)





Pregnancy: any maternal smoking in pregnancy
No 1027 (85.4)
Yes 176 (14.6)







Not detected (no) 993 (82.5)
Detected (yes) 210 (17.5)
Number of omics datasets
6 834 (69.3)
4 or 5 282 (23.4)
2 or 3 25 (2.2)
1 62 (5.10)
*Sex and age z-score calculated according to WHO reference curves
**9.5% out of the 1203 children
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(Table 2). For 93% of the children, omics data from at
least 4 platforms was available (Table 1).
Exposure to tobacco smoking
Out of the 1203 mothers, 14.6% reported having smoked
at some point during pregnancy (any smoking), and
9.5% reported having smoked throughout whole preg-
nancy (sustained smokers) (Table 1). When considering
information on dose and duration during pregnancy
(n = 1193), 55.6% of the mothers were unexposed, 30.2%
were exposed to SHS, 5.2% were non-sustained smokers,
7.8% were sustained smokers at low dose (≤ 9 cigarettes
per day), and 1.3% were sustained heavy smokers
(Fig. 1a).
The frequency of children exposed to global-SHS,
meaning exposure at home or in other places, was 35.4%
(Table 1): 17.2% were exposed only outside home, 10.9%
only at home, and 7% in both places (0.4% did not had
enough information to be classified in any of these cat-
egories) (Fig. 1b). Moreover, 17.5% of the children had
urinary cotinine levels over the limit of detection (LOD)
(Table 1). The correlations of cotinine measures with
global-SHS and home-SHS were 0.7 and 0.8, respectively
(Table 3).
The correlations between in utero and childhood ex-
posures are shown in Table 3. The highest correlation of
maternal smoking in pregnancy was with child cotinine
levels (0.7), then with home-SHS (0.6), and finally with
global-SHS (0.4). Considering a combination of any ma-
ternal smoking in pregnancy and global-SHS exposure
during childhood, 59% of the children were not exposed
to any smoking, 5.6% were exposed only in pregnancy,
26.4% only after birth, and 9.1% in both periods
(Fig. 1c).
The proportion of exposed children was highly
dependent on the cohort (Fig. 1, Additional file 3: Fig.
S3). Southern European cohorts (RHEA-Greece, INMA-
Spain, and EDEN-France) had the highest percentage of
smoking mothers, and maternal or child exposure to
SHS was highest in RHEA, in INMA, and also in
KAUNAS-Lithuania. In MoBa-Norway, only 20.8% of
the children were exposed to prenatal or childhood
tobacco smoke, while in RHEA, this percentage rose to
73.6%.
Association between maternal smoking in pregnancy and
child DNA methylation
Screening and comparison with the literature
After controlling for childhood global-SHS, any and sus-
tained maternal smoking in pregnancy were associated
with altered child blood DNA methylation. Lambda in-
flation factors ranged from 0.951 to 1.003 (Additional
file 3: Fig. S4). At 5% false discovery rate (FDR), a total
of 41 unique CpGs were differently methylated, when
comparing any or sustained maternal smoking in preg-
nancy to non-smoking: 24 were associated with both
smoking definitions, 3 with any, and 14 with sustained,
although all of them were at least nominally significant
in both models (Additional file 1: Table S3). These 41
CpGs were located in 18 loci, defined as regions of < 2
Mb, and were distributed along the genome (Fig. 2).
Around 30% of the CpG sites were hypo-methylated
(lower methylation in exposed children) (Additional file
3: Fig. S4), and CpGs located in the same locus were af-
fected in the same direction, except for the AHRR locus
(Fig. 2). Differential DNA methylation at 17 out of the
18 loci had previously been reported in relation to sus-
tained maternal smoking in pregnancy in cord blood
[15] (Additional file 1: Table S3). Moreover, persistent
effects until childhood were described for 16 of them
[15]. The unique locus not previously related to mater-
nal smoking in pregnancy was FMN1 (Formin 1), but
other CpGs in that locus were found differently methyl-
ated in current smokers in the opposite direction [21].
Thirteen out of the 18 loci (27 out of the 41 CpGs) had
at least one genetic variant (mQTL), in cis and/or trans,
associated with methylation levels (Additional file 1:
Table S3).
Effects of dose and duration
As expected, stronger effects were observed for sustained
maternal smoking in pregnancy compared with any ma-
ternal smoking in pregnancy in 39 out of the 41 CpGs
(Additional file 3: Fig. S5). The mean absolute
Table 2 Sample size and number of features included in each omics dataset
Omics dataset Number of samples Number of features
Initial After QC With data on smoking Initial After QC
Blood DNA methylation 1200 1192 1105 485,512 386,518
Blood gene expression 1176 1158 958 64,568 58,254
Blood miRNA gene expression 961 955 895 2549 1117
Plasma proteins 1212 1188 1103 43 36
Serum metabolites 1209 1208 1128 188 177
Urine metabolites 1212 1211 1131 64,000 44
QC quality control
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percentage change of methylation from any to sustained
maternal smoking in pregnancy models was 32.8% (Add-
itional file 1: Table S3). The effect of dose and/or dur-
ation of maternal smoking in pregnancy on DNA
methylation was investigated. At visual inspection, we
identified 4 different illustrative patterns: (i) CpGs exhi-
biting an increased or decreased DNA methylation ten-
dency with increasing maternal smoking in pregnancy
dose and/or duration (Fig. 3a, b); (ii) CpGs with an in-
creased or decreased DNA methylation tendency only
with increasing dose of sustained maternal smoking in
pregnancy, but without response to any maternal
smoking in pregnancy (Fig. 3c, d); (iii) CpGs with a satu-
rated pattern at any maternal smoking in pregnancy
(Fig. 3e); and (iv) CpGs with a saturated pattern at sus-
tained maternal smoking in pregnancy (Fig. 3f). The
plots for all 41 CpGs are shown in Additional file 4: Fig.
S6 (10 showing a linear trend, 4 with a dose response in
sustained smokers, 3 saturated with any smoking, and 8
saturated with sustained smoking). Some CpGs did not
show a clear pattern, and others located at the same
locus showed different patterns. Maternal exposure to
SHS was only nominally associated (p value < 0.05) with
2 of these 41 CpGs (cg11902777 and cg17454592).
Fig. 1 Percentage of children exposed to different dose and/or duration of tobacco smoking in all children and by cohort: in pregnancy (a), in
childhood (b), and in pregnancy and childhood combined (c). Mat-SHS, mothers exposed to SHS; Non-sust, non-sustained smoker mothers; Sust
(=<9), sustained smoker mothers at low dose—less than or equal to 9 cigarettes per day; Sust (>9), sustained smoker mothers at high
dose—more than 9 cigarettes per day. Other categories are self-explanatory
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Table 3 Correlation among variables of pregnancy and childhood exposure to tobacco smoking













Any maternal smoking in pregnancy 1
Sustained maternal smoking in pregnancy 1* 1
Childhood
exposure
Global-SHS 0.4 0.4 1
Home-SHS 0.6 0.6 1** 1
Urinary cotinine 0.7 0.7 0.7 0.8 1
*Complete cases were used to test the correlation between any and sustained maternal smoking in pregnancy, and since non-sustained smokers are excluded
from sustained maternal smoking in pregnancy, both variables are virtually the same in this comparison
**By definition, all children exposed at home to SHS are also exposed in global-SHS (n = 214); however, unexposed children according to global-SHS are both
exposed (n = 214) and unexposed (n = 777) at home
Fig. 2 Circus plot showing the association between sustained maternal smoking in pregnancy and child blood DNA methylation and transcription along the
chromosomes (outer circle). Second circus shows the statistical significance (−log10(p value)) for DNA methylation (dark blue) and transcription (light blue). Only
the 18 loci significant at 5% FDR in the methylation analysis are annotated. Next circus shows the direction of the association of the CpGs in these 18 loci with
maternal smoking in pregnancy (green, positive; red, inverse; and orange, loci with CpGs associated in both directions). The inner circus shows the 5 loci for
which cis eQTMs at 5% FDR were identified (green, positive, meaning higher DNA methylation–higher gene expression; red, inverse; and orange, both). Genes
annotated in parenthesis are significant eQTM genes, and none of them corresponds to the closest gene to the CpG site. Loci annotated with an asterisk are
those surviving multiple-testing correction only in the any maternal smoking in pregnancy models. To gain graphical resolution, only associations with p value
< 0.05 are shown, and p values < 1E−10 are truncated to 1E−10
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Search for gene expression quantitative trait methylation
We, then, examined whether the 41 CpGs might be
eQTMs. A total of 480 unique transcript clusters (TCs,
equivalent to known or putative genes) with their transcrip-
tion start site (TSS) within ± 500 kb of the 41 CpGs were
identified. At 5% FDR, 15 methylation to expression rela-
tionships were found, which included 12 unique CpGs in 5
loci and 7 unique TCs (Fig. 2, Additional file 1: Table S4).
All eQTMs, except cg21161138 (AHRR)-TC05002792.hg.1,
occurred between CpGs and genes located at < 160 kb
(Additional file 3: Fig. S7). None of the eQTMs genes corre-
sponded to the most proximal gene to the CpG site. Two
out of the 15 eQTM relationships were inverse, meaning
higher methylation-lower gene expression, while the others
were positive. The inverse associations were between
PNOC and a CpG (cg17199018) located downstream the
gene, and between EXOC3 and a CpG (cg11902777) lo-
cated upstream.
Fig. 3 Box plots showing the change of child blood DNA methylation compared to unexposed mothers (y-axis) by categories of dose and/or
duration of exposure to tobacco smoking in pregnancy (x-axis), adjusted for global-SHS. Horizontal line in the middle of the boxes shows the
mean difference in DNA methylation with respect to the reference category of unexposed mothers. Boxes represent the DNA methylation
change ± standard error (SE), and vertical lines indicate extreme changes defined as ± 3 × SE. Each graph shows an illustrative pattern: a tendency
of increased methylation with increased dose and/or duration, b tendency of decreased methylation, c tendency of increased methylation only in
sustained maternal smoking in pregnancy, d tendency of decreased methylation only in sustained maternal smoking in pregnancy, e saturated
pattern in non-sustained smokers, and f saturated pattern in sustained maternal smoking in pregnancy. The rest of the 41 CpGs can be found in
Additional file 4 (Fig. S6). Mat-SHS, mothers exposed to SHS; Non-sust, non-sustained smoker mothers; Sust (=<9), sustained smoker mothers at
low dose—less than or equal to 9 cigarettes per day; Sust (> 9), Sustained smoker mothers at high dose—more than 9 cigarettes per day. Other
categories are self-explanatory
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With a nominal p value < 0.05, 65 other eQTMs were
detected, in total, involving 33 unique CpGs in 14 out of
the 18 loci (Additional file 1: Table S4). Only the methy-
lation levels of CpGs at the gene body of GFI1 and
AHRR were associated with the expression of the same
genes. AHRR, associated with maternal smoking in preg-
nancy [15] and current smoking in adults [21], is an in-
teresting example. Five CpGs in the AHRR locus were
associated with maternal smoking in pregnancy: 2
hyper-methylated located at intron 1 (cg17924476,
cg23067299), and 3 hypo-methylated at other introns
(cg11902777, cg05575921, cg21161138) (Fig. 4). Hyper-
methylated CpGs in relation to maternal smoking in
pregnancy were positive eQTMs for AHRR, PDCD6, and
EXOC3 genes, while hypo-methylated CpGs were inverse
eQTMs for the same genes (in both cases implying
higher expression of the genes).
Association between maternal smoking in pregnancy and
other child molecular phenotypes
Besides child DNA methylation, we also screened the as-
sociation between maternal smoking in pregnancy and the
other molecular layers: gene and miRNA transcription,
plasma proteins, and serum and urinary metabolites.
After multiple-testing correction, only 2 associations
between maternal smoking in pregnancy and urinary
metabolites were detected. Urinary alanine and lactate
were increased in children of mothers classified as sus-
tained smokers during pregnancy compared to children
of non-smoking mothers (effect = 0.189 and 0.174, p
value = 3.93E−04 and 5.19E−04, respectively) (Additional
file 1: Table S5).
No associations were found between maternal smok-
ing in pregnancy and child serum metabolites or blood
gene/miRNA expression. However, given the effect of
maternal smoking on child methylation and the eQTM
analyses, we took a closer look at gene expression (Fig.
2). Top 10 associations can be seen in Additional file 1:
Table S6, and among the 15 eQTM genes, only EXOC3
was nominally downregulated in children of smoker
mothers (p value < 0.01) (Additional file 1: Table S7).
Association between childhood exposure to SHS and
child molecular phenotypes
In postnatal life, childhood SHS exposure was related to
child plasma protein and serum metabolite levels, but
not to any other of the molecular layers (blood DNA
methylation, gene/miRNA transcription, or urinary
metabolites).
In particular, higher levels of PAI1 (plasminogen acti-
vator inhibitor-1) protein were found in children with
urinary cotinine levels above the LOD compared to
those below the LOD (effect = 0.379, p value = 1.66E−04)
(Additional file 1: Table S8). PAI1 levels increased with
increased frequency of exposure, with children exposed
both inside and outside home having the highest PAI1
levels (Fig. 5). This association was attenuated when
testing global-SHS instead of urinary cotinine levels.
On the other hand, children classified as exposed to
SHS under different definitions had lower levels of sev-
eral serum metabolites compared to those classified as
not exposed [global-SHS: sphingomyelin (OH) C16:1 (ef-
fect = − 0.073, p value = 7.97E−05), carnitine C9 (effect =
− 0.052, p value = 8.03E−04), and cotinine: PC ae C38.0
(effect = − 0.110, p value = 7.88E−04)] (Additional file 1:
Table S8). We only detected a clear pattern of a dose-
effect response for carnitine C9 (Fig. 5).
Comparison and enrichment for signals identified in
current smokers
We, then, compared our results of exposure to to-
bacco smoke in children, both in pregnancy and in
postnatal life, with the molecular marks identified for
current smoking in adults. For serum metabolites [19]
and miRNAs [22], molecular layers with a limited
number of marks assessed in the omics platforms, we
did a direct comparison of the findings. For genome-
wide omics, we analyzed whether our findings showed
any enrichment for the signals identified in studies of
current smoking and DNA methylation (N = 16,223
CpGs at 5% FDR) [21], and gene expression (N = 1270
genes at 10% FDR) [20].
As in current smokers [19], children exposed to
postnatal SHS had lower levels (p value < 0.05) of
diacyl (aa)-phosphatidylcholines (PC aa C36:0, PC aa
C38:0), acyl-alkyl (ae)-phosphatidylcholines (PC ae
C38:0, PC ae C38:6, PC ae C40:6), and sphingomye-
lin (OH) C22:2 (Additional file 1: Table S9) com-
pared to non-exposed children. None of the amino
acids reported to be increased in current smokers
were affected in SHS-exposed children. In contrast
to this, maternal smoking in pregnancy had no effect
on serum metabolites related to current smoking
(Additional file 1: Table S10).
None of the miRNAs for current smoking were
nominally significant in our study, either with expos-
ure pregnancy or in childhood (Additional file 1:
Table S11 and Table S12). Similarly, no enrichment
for current smoking sensitive genes was observed
among our results of exposure during pregnancy (en-
richment p values for any and sustained maternal
smoking, 0.903 and 0.842, Additional file 3: Fig. S8)
or our results of exposure to childhood SHS (enrich-
ment p values for global-SHS and child cotinine,
0.579 and 0.746, Additional file 3: Fig. S9).
Regarding DNA methylation, we also found that our
results for childhood SHS were not enriched for
CpGs associated with current smoking (enrichment p
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values for global-SHS and child cotinine, 0.034 and
0.998) (Additional file 3: Fig. S10). In contrast, we ob-
served enrichment among our list of CpGs associated
with maternal smoking in pregnancy (enrichment p
values for any and sustained maternal smoking in
pregnancy, 2.834E−07 and < 2.2E−16, respectively)
(Additional file 3: Fig. S11). In particular, the DNA
methylation at 1279 of the 16,223 current smoking
sensitive CpGs [21] was nominally significant in chil-
dren of sustained smoker mothers, 73.3% of them
with consistent direction of the effect, and with a
lambda inflation factor of 1.16.
Fig. 4 Regional plot of the AHRR locus (50 kb upstream and downstream of the 5 CpG sites associated with any maternal smoking in pregnancy).
The y-axis of the top panel shows the −log (10) p value of the associations between any maternal smoking in pregnancy and methylation levels
at CpG sites (circles) and gene expression levels (lines). Only CpGs nominally associated (p value < 0.05) are shown, hyper-methylated in red and
hypo-methylated in blue. The top CpG, cg05575921, is shown in purple. Five of the CpGs survived multiple-testing correction (dashed red line): 2
hyper-methylated in intron 1 (cg17924476 and cg23067299), and 3 hypo-methylated at other introns (cg11902777, cg05575921, and cg21161138).
The correlation of methylation levels among CpGs is shown at the bottom panel. The middle panel shows the annotation of genes (yellow) and
CpG islands (green). The expression of none of the genes in the locus for which there were probes in the gene expression array was associated
with any maternal smoking in pregnancy (p value < 0.05). All of them showed negative coefficients of the association (indicated as pink lines). List
of TCs and gene annotation: TC05001094.hg.1 annotated to EXOC3-AS1, TC05000006.hg.1 annotated to EXOC3, TC05000005.hg.1 annotated to
both AHRR and PDCD6, and TC05002795.hg.1 not annotated
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Sensitivity analyses for pregnancy and childhood
exposure to smoking
We conducted further sensitivity analyses for the mo-
lecular marks that survived multiple-testing correc-
tion. First, we ran additional pregnancy models
adjusting for home-SHS instead of global-SHS. In
general, the strength of the association was reduced,
but for DNA methylation, the change in effect size
between models was low (mean absolute percentage
change < 5%) (Additional file 3: Fig. S12, Additional
file 1: Table S13-S14).
Second, we compared adjusted and unadjusted models
for exposure to smoking in the reciprocal period. For ma-
ternal smoking in pregnancy, mainly associated with DNA
methylation levels, results were practically the same be-
tween models, again, with mean absolute percentage
change < 5% (Additional file 3: Fig. S13, Additional file 1:
Table S15-S16). For postnatal SHS, adjustment for sus-
tained maternal smoking in pregnancy, in general, attenu-
ated the effect sizes to a maximum of around 20% change
(Additional file 1: Table S17).
Third, we repeated the analysis restricting the sample
to children of European ancestry (N = 1083) (Additional
file 1: Table S18-S20). In general, p values were
attenuated, likely due to a smaller samples size, but ef-
fect sizes remained of similar magnitude (mean absolute
percentage change < 5%) (Additional file 3: Fig. S14,
Additional file 1: Table S18). The other biomarkers
showed more heterogeneous patterns when evaluated in
children of European ancestry only, with some of them
showing an increase of the effect (Additional file 1:
Table S19-S20).
Discussion
Despite the efforts of public health campaigns, maternal
smoking in pregnancy and childhood SHS are still main
adverse avoidable risk factors for child health. This study
is the first to examine the association of exposure to to-
bacco smoking at different windows of exposure, in
utero and in childhood, with multi-layer molecular
phenotypes.
Exposure to maternal smoking in pregnancy was asso-
ciated with DNA methylation of 41 CpG sites located in
18 different loci. All loci had previously been related to
maternal smoking during pregnancy [14–16] or current
smoking [21]. However, none of the previous studies
had incorporated substantial transcriptomics data from
the same subjects to interpret the functional
Fig. 5 Box plots showing the change of child protein/metabolite levels compared to unexposed mothers (y-axis) by categories of dose and/or
duration of exposure to SHS (x-axis), adjusted for sustained maternal smoking in pregnancy. Horizontal line in the middle of the boxes shows the
mean difference in protein/metabolite levels with respect to the reference category of unexposed mothers. Boxes represent the protein/
metabolite change ± standard error (SE), and vertical lines indicate extreme changes defined as ± 3 × SE. b Plasma PAI1 levels, b serum C9,
c serum SM (OH) C16:1, and d serum PC ae C38:0
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consequences of these epigenetic changes. Furthermore,
few studies investigated duration and intensity of mater-
nal smoking in pregnancy, which might be relevant for
public health advice [14, 16].
As in cord blood [14, 16], sustained maternal smoking
in pregnancy produced larger effects on childhood blood
DNA methylation than any maternal smoking, with the
latter group including sustained smoker mothers as well
as mothers that usually only smoked during the 1st tri-
mester. Moreover, when considering duration and inten-
sity of maternal smoking in pregnancy, some CpGs
showed a dose-response trend, whereas others got satu-
rated with any maternal smoking in pregnancy or did
not have any meaningful response. These heterogeneous
patterns, even in the same locus, can be explained by
CpG-specific responses, but also by less accuracy in the
measurement of some CpGs (low biological response to
high technical noise) [66]. In any case, the persistence
and the linear trend response of CpGs in MYO1G,
GNG12, AHRR, FRMD4A, RADIL, and 7q11.22 make
them interesting candidates for the development of an
epigenetic biomarker for in utero exposure to smoking
[10]. In general, maternal SHS during pregnancy had
mostly negligible effects on offspring blood DNA methy-
lation at the 41 significant CpGs, or at least their effects
were diluted over time and not detected in childhood
with the actual sample size.
We also observed that DNA methylation in 5 of these
18 loci was related to gene expression of nearby genes, but
usually not of the closest annotated gene. However, these
effects were weak as we did not detect significant associa-
tions between maternal smoking in pregnancy and expres-
sion of these genes. In other words, DNA methylation
response to maternal smoking in pregnancy was not mir-
rored at the transcriptional level of nearby genes. Simi-
larly, previous studies in former smokers have shown that
smoking has a longer-lasting influence on the methylome
compared to the transcriptome [67]. The reversal rate of
gene expression at 1 year after smoking cessation has been
calculated in > 50% and reaches > 85% after 10 years,
whereas for methylation, it ranges from 17 to 33% with
some effects still visible 40 years after smoking cessation.
The different reversal rates between methylation and tran-
scription could be explained by the complex transcrip-
tional regulation that involves mechanisms other than
DNA methylation. Whether persistent epigenetic marks
act as a memory of the cell to previous exposures, to trig-
ger rapid or amplified transcriptional activation in certain
contexts (i.e., after a second exposure event), is unknown.
Also, the weak association between exposure to tobacco
smoke and transcription, in comparison to methylation,
might be explained by the highest instability of the RNA
compared to DNA, which might have introduced noise
into the transcriptional data.
AHRR (Aryl-Hydrocarbon Receptor Repressor), which is
involved in xenobiotic detoxification, cell growth, and
differentiation, has widely been reported in relation to
smoking. In particular, cg05575921 has been found to be
hypo-methylated in cord blood [15], adult blood [21], pla-
centa [13], and adipose tissue [67]. AHRR is an interesting
example to discuss the complexity of epigenetic regulation.
First, in our study, AHRR exhibited both hyper-methylation
(intron 1) and hypo-methylation (other introns) in response
to smoking. Through the eQTM analyses, we found that
both hyper- and hypo-methylation were related to in-
creased expression of the gene in blood. This finding evi-
dences that epigenetic regulation of transcription is gene
context-specific (i.e., intron 1 behaves different from other
introns) and that methylation-expression correlations are
fundamental to understand final transcriptional conse-
quences. Second, besides AHRR gene, methylation at CpGs
of this locus was also associated with the expression of two
other nearby genes: PDCD6 and EXOC3. PDCD6 (Pro-
grammed Cell Death 6) is a calcium sensor involved in
endoplasmic reticulum (ER)-Golgi vesicular transport,
endosomal biogenesis, or membrane repair, and EXOC3
(Exocyst Complex Component 3) is a component of the
exocyst complex involved in the docking of exocytic vesi-
cles with fusion sites on the plasma membrane. Further re-
search might clarify the potential role of these genes, if any,
in relation to tobacco smoking.
Two metabolites (lactate and alanine), known to be in-
creased with glycemic dysregulation [68], were found at
higher levels in urine of children born from sustained
smoker mothers compared with non-smokers. Although
there are some studies reporting an association between
maternal smoking and type 2 diabetes and metabolic
syndrome, the evidences are still inconclusive according
to a recent meta-analysis [69].
In contrast to in utero exposure, exposure to childhood
SHS, assessed through either questionnaire or cotinine,
was associated with child serum metabolites and plasma
proteins. In particular, we found that SHS, defined as urin-
ary cotinine above the LOD, increased plasma PAI1 (plas-
minogen activator inhibitor-1 SERPINE1 gene) protein
levels. PAI1 is the principal inhibitor of tissue plasmino-
gen activator (tPA) and urokinase (uPA), enzymes that
convert plasminogen into plasmin (fibrinolysis) (Add-
itional file 3: Fig. S15). Therefore, higher levels of PAI1 are
indicative of a thrombotic state, and they have been found
in active smokers [70, 71]. Although the increase of
plasma PAI1 levels in SHS-exposed children was substan-
tially smaller than the increase detected in active smokers
[70], our findings evidence that SHS was sufficient to pro-
duce a pro-thrombotic state in children. The long-term
consequences of this pro-thrombotic state in children, if
prolonged over time, are unknown, but in adults, it is
linked to age-related subclinical (i.e., inflammation or
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insulin resistance) or clinical (i.e., myocardial infarction,
obesity) conditions [72].
We also found several serum metabolites altered in
SHS-exposed children. Reduced levels of diacyl (aa)- and
acyl-alkyl (ae)-phosphatidylcholines and of sphingomye-
lin (OH) C22:2 were in agreement with findings in active
adult smokers [19]. Is it worth noting that these diacyl
(aa)- and acyl-alkyl (ae)-phosphatidylcholines overlap
with those positively associated with adherence to Medi-
terranean diet and with protective risk factors for cardio-
vascular disease [73]. We considered the reported
location of childhood SHS exposure (inside home, out-
side, and in both places) as a surrogate of intensity of ex-
posure to smoking. While PAI1 plasma protein levels
and carnitine C9 were higher in children exposed in
both locations, no clear dose-response patterns were ob-
served for other metabolites.
Given that SHS effects might be subtler than those of
active smoking, we also examined whether molecular fea-
tures (CpG methylation or gene/miRNA transcription) de-
scribed in current smokers overlapped with our findings
of postnatal SHS with a less stringent p value cutoff. We
did not detect any enrichment, suggesting that if postnatal
SHS has an effect on these molecular layers, our sample
size is too limited to detect it. Conversely, as an indication
of the long-term and strong effects of active smoking, we
did find enrichment for child CpGs associated with mater-
nal smoking in pregnancy among CpGs described for
current smoking in other studies. Indeed, it has been de-
scribed a remarkable overlap between the blood methyla-
tion signatures detected in adult smokers and in
newborns of smoker mothers [74].
Globally, our findings together with previous literature
suggest that offspring blood DNA methylation captures
strong and permanent effects associated with active ma-
ternal smoking during pregnancy. In our study, the asso-
ciations between maternal smoking during pregnancy
and DNA methylation were not attenuated after adjust-
ment for childhood SHS, likely due the weaker effects of
passive compared to active smoking. In contrast, the po-
tential biological effects of SHS were best captured by
dynamic molecules with fast responses, such as metabo-
lites and proteins. Time-course studies will be needed to
dissect this acute response in more detail. Adjustment
for maternal smoking during pregnancy attenuated the
effects of childhood SHS on these markers, highlighting
the importance of mutually adjusted models in order to
identify period-specific effects.
Findings should be considered within the context of the
study’s limitations. First, exposure assessment to tobacco
smoking, through either questionnaire or cotinine, has
some intrinsic limitations. Maternal smoking in pregnancy
and child exposure to SHS were self- or parental-reported,
and they can be subject to misreporting [75]. Urinary
cotinine, although more objective, only provides informa-
tion about the most recent exposure (half-life in urine ~
20 h) [8]. In our study, cotinine detection correlated
strongly with the childhood SHS classification though, giv-
ing us reasonable confidence in the questionnaire reports.
Second, we aimed to dissect pregnancy from childhood
exposure associations using mutually adjusted models.
However, misclassification and weaker effects of SHS
compared to effects of maternal smoking in pregnancy
(i.e., PAI1 or AHRR [23]), as well as the high level of over-
lap between maternal and childhood smoking exposure,
might have limited our ability to distinguish between these
two time periods. Larger samples of children exposed to
SHS, without in utero exposure, might be needed to inves-
tigate SHS, especially for DNA methylation. Third, al-
though the statistical models were adjusted for an
exhaustive list of confounders, including child zBMI, we
cannot completely rule out residual confounding. For ex-
ample, plasma PAI1, which can be released by fat cells
[76], is related to BMI and percent body fat [77]. Fourth,
although the study has been designed as a comprehensive
screening using high-throughput omics platforms, these
platforms do not have complete coverage of the molecular
layers, and consequently, we might have missed some bio-
logical signals. Also, cell type-specific responses might
have been diluted within the context of whole blood ana-
lyses. Fifth, some of the smoking sensitive CpGs de-
tected in our study are known to be regulated by
mQTLs. The role of genetic variation in modifying
the effects of the exposure to smoking deserves future
research. Finally, our study predominantly consisted
of European ancestry children, and thus, additional
studies involving diverse ethnic backgrounds are
needed in order to improve the generalizability of the
findings. Potential confounding by ancestry was con-
trolled by adjusting the models for self-reported eth-
nic origin. For the top signals, we also performed a
sensitivity analysis restricted to European ancestry
children and results did not change substantially.
Conclusions
Our study investigated the in utero and postnatal effects
of exposure to tobacco smoke on 4 molecular layers,
assessed through a harmonized protocol, in 1203 chil-
dren across Europe. Our results confirmed previous
findings of persistent associations between maternal
smoking in pregnancy and childhood blood DNA
methylation and showed dose-response trends at some
CpG sites. These might be informative for the develop-
ment of an epigenetic risk score of in utero exposure to
tobacco smoke. The persistent methylation signature re-
lated to in utero exposure to smoking was not mirrored
at the transcriptional level. The meaning of the gap be-
tween methylation and transcriptional signals requires
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further investigation, but might mean a methylation-
based memory of the cell. Childhood SHS was not re-
lated to blood methylation, indicating much weaker ef-
fects of recent SHS with respect to active maternal
smoking in pregnancy. In contrast, childhood SHS was
related to higher plasma levels of PAI1, a protein that in-
hibits fibrinolysis, and to certain metabolites. The final
clinical impact of sustained increased levels of PAI1 in
children is unknown, but this finding highlights the im-
portance of the analysis of molecular traits to capture
subtler effects at earlier timepoints.
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adjusted for global-SHS. Table S16. Association of maternal smoking in
pregnancy and child molecular phenotypes unadjusted for global-SHS.
Table S17. Association of childhood SHS and child molecular pheno-
types unadjusted for sustained maternal smoking in pregnancy. Table
S18. Association of maternal smoking in pregnancy and child DNA
methylation levels in European ancestry children adjusted for global-SHS.
Table S19. Association of maternal smoking in pregnancy and child mo-
lecular phenotypes in European ancestry children adjusted for global-
SHS. Table S20. Association of childhood SHS and child molecular phe-
notypes in European ancestry children adjusted for sustained maternal
smoking in pregnancy
Additional file 2 Additional Methods.
Additional file 3: Additional Fig. S1-S5 and Fig. S7-S15. Fig. S1.
Directed acyclic graph (DAG) with causal assumptions from a priori
knowledge between maternal smoking during pregnancy (MSDP) and
child molecular features. In blue, the causal path assessed in the model.
Fig. S2. Directed acyclic graph (DAG) with causal assumptions from a
priori knowledge between childhood SHS and child molecular features.
Fig. S3. Percentage of children exposed to tobacco smoking in the
study population and by cohort: any (A) and sustained (B) maternal
smoking during pregnancy (MSDP), childhood global-SHS (C), and child
urinary cotinine measurements (D). Fig. S4. QQ-plot and Volcano-plot of
the associations between child DNA methylation and any (A and B) and
sustained (C and D) maternal smoking during pregnancy (MSDP), ad-
justed for global-SHS. Fig. S5. Comparison of effects on child blood DNA
methylation between any and sustained maternal smoking during preg-
nancy (MSDP), adjusted for global-SHS. Fig. S7. Plot showing significance
of methylation to expression relationships (−log10(p-value)) in relation to
the distance between TC-TSS and CpG. Fig. S8. QQ-plot of the associa-
tions between child blood gene expression and global-SHS (A) and urin-
ary cotinine (B), adjusted for sustained maternal smoking during
pregnancy (MSDP), among 1270 genes identified in current smokers at
10% FDR (Huan et al. 2016). Fig. S9. QQ-plot of the associations between
child blood DNA methylation and global-SHS (A) and urinary cotinine (B),
adjusted for sustained maternal smoking during pregnancy (MSDP),
among 18,763 CpGs identified in current smoking at 5% FDR (Joehanes
et al. 2016). Fig. S10. QQ-plot of the associations between child blood
DNA methylation and any (A) and sustained (B) maternal smoking during
pregnancy (MSDP), adjusted for global-SHS, among 18,763 CpGs identi-
fied in current smoking at 5% FDR (Joehanes et al. 2016). Fig. S11. Inter-
action between any maternal smoking during pregnancy (MSDP) and
global-SHS. The y-axis shows predicted methylation levels at cg01664727
(at RUNX1 locus). Fig. S12. Comparison of effects of maternal smoking
during pregnancy (MSDP) on child blood DNA methylation between
models adjusted for global-SHS and for home-SHS. Fig. S13. Comparison
of effects of maternal smoking during pregnancy (MSDP) on child blood
DNA methylation between models adjusted for global-SHS and un-
adjusted model. Fig. S14. Comparison of effects of maternal smoking
during pregnancy (MSDP) on child blood DNA methylation between
datasets including all children and including only European ancestry chil-
dren. Fig. S15. Schematic representation of PAI1 cascade. In red inhib-
ition steps and in green activation steps.
Additional file 4: Fig. S6. Fig. S6. Box plots showing the change of
child blood DNA methylation compared to unexposed mothers at 41
CpGs (y-axis) by categories of dose and/or duration of exposure to
tobacco smoking in pregnancy (x-axis), adjusted for global-SHS. Horizon-
tal line in the middle of the boxes shows the mean difference in DNA
methylation with respect to the reference category of unexposed
mothers. Boxes represents the DNA methylation change ± standard error
(SE), and vertical lines indicate extreme changes defined as ±3xSE. Le-
gend: Mat-SHS (mothers exposed to SHS), Non-sust (non-sustained
smoker mothers), Sust (= < 9) (Sustained smoker mothers at low dose –
less than or equal to 9 cigarettes per day), Sust (> 9) (Sustained smoker
mothers at high dose – more than 9 cigarettes per day). Other categories
are self-explanatory.
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